Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

被引：14

作者：

Pantano, Francesco ^{[1
]}

Russano, Marco ^{[1
]}

Berruti, Alfredo ^{[2
]}

Mansueto, Giovanni ^{[3
]}

Migliorino, Maria R. ^{[4
]}

Adamo, Vincenzo ^{[5
,6
]}

Aprile, Giuseppe ^{[7
,8
]}

Gelibter, Alain ^{[9
]}

Ficorella, Corrado ^{[10
,11
]}

Falcone, Alfredo ^{[12
]}

Russo, Antonio ^{[13
]}

Aieta, Michele ^{[14
]}

Maio, Michele ^{[15
]}

Martelli, Olga ^{[16
]}

Barni, Sandro ^{[17
]}

Napolitano, Andrea ^{[1
]}

Roca, Elisa ^{[2
]}

Quadrini, Silvia ^{[3
]}

Iacono, Daniela ^{[4
]}

Russo, Alessandro ^{[5
,6
]}

Calvetti, Lorenzo ^{[7
,8
]}

Occhipinti, Mario A. ^{[9
]}

Cortellini, Alessio ^{[10
,11
]}

Vasile, Enrico ^{[12
]}

Passiglia, Francesco ^{[13
]}

Imperatori, Marco ^{[14
]}

Calabro, Luana ^{[15
]}

Di Giacomo, Anna M. ^{[15
]}

Petrelli, Fausto ^{[17
]}

Pasquini, Giulia ^{[12
]}

Franchina, Tindara ^{[5
,6
]}

Venditti, Olga ^{[10
,11
]}

Intagliata, Salvatore ^{[2
]}

Galvano, Antonio ^{[13
]}

Fioroni, Iacopo ^{[1
]}

Vincenzi, Bruno ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Santini, Daniele ^{[1
]}

机构：

[1] Univ Campus Biomed, Dept Med Oncol, Via Alvaro Del Portillo 200, I-00128 Rome, Italy

[2] Univ Brescia, ASST Spedali Civili, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, Brescia, Italy

[3] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[4] St Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[5] Univ Messina, Med Oncol Unit AO Papardo, Messina, Italy

[6] Univ Messina, Dept Human Pathol, Messina, Italy

[7] Univ & Gen Hosp, Dept Oncol, Udine, Italy

[8] San Bortolo Gen Hosp, Dept Oncol, ULSS8 Berica, Vicenza, Italy

[9] Policlin Umberto 1, Med Oncol Unit, Rome, Italy

[10] St Salvatore Hosp, Med Oncol Unit, Laquila, Italy

[11] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[12] Azienda Osped Univ Pisana, Unit Oncol 2, Pisa, Italy

[13] Univ Palermo, Dept Surg & Oncol Sci, Sect Med Oncol, Palermo, Italy

[14] IRCCS CROB, Referral Canc Ctr Basilicata, Div Med Oncol, Dept Oncohematol, Rionero, Vulture, Italy

[15] Univ Hosp Siena, Ctr Immunooncol Med Oncol & Immunotherapy, Dept Oncol, Siena, Italy

[16] Azienda Osped San Giovanni Addolorata, Med Oncol Unit, Rome, Italy

[17] Azienda Osped Treviglio, Div Oncol, Treviglio, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2020年 / 20卷 / 03期

关键词：

Immunotherapy; Nivolumab; non-Small-Cell Lung Cancer; malignant pleural effusion; IMMUNE CHECKPOINT INHIBITORS; PLEURAL EFFUSION; EFFICACY; DOCETAXEL; SURVIVAL; TRIALS;

D O I：

10.1080/14712598.2020.1724953

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

引用

页码：319 / 326

页数：8

共 24 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2]

Brahmer J, 2017, 2017 AACR ANN M APR

[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[4] Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? [J].

Chae, Young Kwang ;

Pan, Alan ;

Davis, Andrew A. ;

Raparia, Kirtee ;

Mohindra, Nisha A. ;

Matsangou, Maria ;

Giles, Francis J. .

CLINICAL LUNG CANCER, 2016, 17 (05) :350-361

[5] Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma [J].

DeLong, P ;

Carroll, RG ;

Henry, AC ;

Tanaka, T ;

Ahmad, S ;

Leibowitz, MS ;

Sterman, DH ;

June, CH ;

Albelda, SM ;

Vonderheide, RH .

CANCER BIOLOGY & THERAPY, 2005, 4 (03) :342-346

[6] Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis [J].

Elias, Rawad ;

Giobbie-Hurder, Anita ;

McCleary, Nadine Jackson ;

Ott, Patrick ;

Hodi, F. Stephen ;

Rahma, Osama .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[7] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[8] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[9] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[10] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer [J].

Herzberg, Benjamin ;

Campo, Meghan J. ;

Gainor, Justin F. .

ONCOLOGIST, 2017, 22 (01) :81-88

← 1 2 3 →